Skip to content

IDEAYA Biosciences, Inc. IDYA Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
$3M-25.0%
Erasca, Inc. logo
Erasca, Inc.ERAS
$746K-62.4%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$782K-51.0%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$4.22M+42.2%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1M-50.0%
Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments?
IDEAYA Biosciences, Inc. (IDYA) reported accretion (amortization) of discounts and premiums, investments of $1.21M in Q1 2026.
How has IDEAYA Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
IDEAYA Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 67.9% year-over-year, from $3.78M to $1.21M.
What is the long-term trend for IDEAYA Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments?
Over 4 years (2021 to 2025), IDEAYA Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 52.7% compound annual growth rate (CAGR), from -$1.83M to $9.98M.
What does accretion (amortization) of discounts and premiums, investments mean?
This represents the non-cash adjustment to interest income or expense resulting from the amortization of premiums or accretion of discounts on debt securities held as investments. It reflects the gradual adjustment of the carrying value of investment securities toward their face value over time. This metric is essential for reconciling net income to operating cash flow by isolating the non-cash impact of investment yield adjustments.